– Q4 and full year 2023 product revenue (DAXXIFY® and RHA® Collection) of $58.5 million and $212.7 million, representing approximately 28% and 80% YoY growth, respectively. – Q4 DAXXIFY volume up 22% ...
NASHVILLE, Tenn., Jan. 13, 2026 /PRNewswire/ -- Revance and Teoxane announce the FDA approval of RHA ® Dynamic Volume from the Teoxane RHA ® Collection for cheek augmentation and/or the correction of ...
"The development of the Teoxane RHA ® Collection with Mepivacaine exemplifies Teoxane's commitment to innovation," states Valérie Taupin, Founder and CEO of Teoxane. "Mepivacaine represents the first ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that its data will be ...
I tried RHA lip filler after regretting my first filler experience. Here’s my honest review, including before-and-after ...
Teoxane today announced the publication in the Aesthetic Surgery Journal of a pivotal randomized, controlled, double-blinded trial evaluating the safety and effectiveness of RHA® 3 for lip ...
- Supports Revance’s commitment to ensuring safety and efficacy of aesthetic product portfolio among diverse patient populations - NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results